Avid Bioservices Inc (CDMO)

[EYEBUYSTOX]

MOS projections for bavi+Sorafenib...

If 34 of 38 patients were enrolled on March 12, 2014, enrollment completed on September 9, 2014 and as of the abstract deadline for the Yopp Houston presentation (September 26, 2014) 7 patients were still receiving treatment, we can deduct that at least 3 patients in the study will have an OS figure of 6.5 months or greater.

We also have OS numbers from the sampling of patients in the SITC poster. We also know that one patient was on treatment for 18 months according to the March 14 PR. Here's my MOS worst case projection:

6.5
6.5
6.5
6.0
9.6
5.3
8.0
3.0
2.7
18.0

MOS of the 10 patients we know is no less than 7.2 months.

I don't know how well that will be received considering sorafenib alone in a phase 3 trial showed a 10 month MOS here:

http://www.ncbi.nlm.nih.gov/pubmed/18650514